In the current study we compared the two methods of assessing Ki-67 LIs: the hot spot method, scoring Ki-67 LIs in a single hot spot only vs. the average method, scoring Ki-67 LIs in multiple areas including hot spot, to determine which method is more appropriate for assessing the prognoses of luminal/HER2-negative breast cancers. The gene discussed is ERBB2; the disease is breast cancer.